Odefsey
Drug
Gilead Sciences Inc
Total Payments
$9.2M
Transactions
2,807
Doctors
98
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $3,468 | 3 | 0 |
| 2020 | $3,010 | 2 | 0 |
| 2019 | $35,805 | 19 | 0 |
| 2018 | $787,837 | 245 | 1 |
| 2017 | $8.3M | 2,538 | 98 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.0M | 2,599 | 98.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $98,960 | 53 | 1.1% |
| Travel and Lodging | $14,166 | 46 | 0.2% |
| Food and Beverage | $9,697 | 109 | 0.1% |
Payments by Type
Research
$9.0M
2,599 transactions
General
$122,823
208 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects | Gilead Sciences Inc | $4.5M | 1 |
| A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) | Gilead Sciences Inc | $2.5M | 1 |
| A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co infected Subjects who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) prior to LDV/SOF HCV Treatment, the HIV/HCV Co STARs study (Co-infection treatment with Single Tablet Antiviral Regimens) | Gilead Sciences Inc | $1.2M | 1 |
| A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) | Gilead Sciences, Inc. | $327,562 | 1 |
| A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects | Gilead Sciences, Inc. | $266,909 | 0 |
| A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co infected Subjects who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) prior to LDV/SOF HCV Treatment, the HIV/HCV Co STARs study (Co-infection treatment with Single Tablet Antiviral Regimens) | Gilead Sciences, Inc. | $235,650 | 0 |
Top Doctors Receiving Payments for Odefsey — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Infectious Disease | Newark, NJ | $1,676 | 3 |
| , MD | Internal Medicine | San Diego, CA | $1,651 | 3 |
| , M.D | Internal Medicine | Cincinnati, OH | $1,638 | 3 |
| , MD | Medical | Phoenix, AZ | $1,625 | 2 |
| , MD | Family Medicine | New York, NY | $1,620 | 2 |
| Phuong Trinh | Infectious Disease | Silver Spring, MD | $1,606 | 3 |
| , MD, PHD | Infectious Disease | Seattle, WA | $1,605 | 2 |
| , MD | Internal Medicine | Brooklyn, NY | $1,601 | 2 |
| , M.D | Public Health or Welfare | Gainesville, FL | $1,594 | 2 |
| , MD | Infectious Disease | Jacksonville, FL | $1,584 | 2 |
| , M.D.P.A | Infectious Disease | Jersey City, NJ | $1,555 | 3 |
| , M.D | Infectious Disease | Tucker, GA | $1,541 | 2 |
| , MD | Internal Medicine | Daytona Beach, FL | $1,540 | 2 |
| , M.D | Family Medicine | Asheville, NC | $1,525 | 2 |
| , M.D | General Practice | Los Angeles, CA | $1,524 | 2 |
| , MD | Family Medicine | Hoboken, NJ | $1,514 | 2 |
| , D.O | Internal Medicine | Lansing, MI | $1,510 | 2 |
| , MD | Internal Medicine | Melbourne, FL | $1,153 | 2 |
| , MD | Family Medicine | Miami, FL | $750.00 | 1 |
| , MD | Infectious Disease | Miami, FL | $234.61 | 2 |
| , MD | Legal Medicine | Delray Beach, FL | $221.58 | 2 |
| , M.D | Infectious Disease | Newark, NJ | $212.69 | 2 |
| , M.D | Family Medicine | Los Angeles, CA | $201.30 | 2 |
| , M.D | Family Medicine | Hollywood, CA | $201.30 | 2 |
| , M.D.,M.P.H | Addiction Medicine | Bronx, NY | $125.00 | 1 |
Ad
Manufacturing Companies
- Gilead Sciences Inc $8.3M
- Gilead Sciences, Inc. $830,121
Product Information
- Type Drug
- Total Payments $9.2M
- Total Doctors 98
- Transactions 2,807
About Odefsey
Odefsey is a drug associated with $9.2M in payments to 98 healthcare providers, recorded across 2,807 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2021. In 2021, $3,468 was paid across 3 transactions to 0 doctors.
The most common payment nature for Odefsey is "Unspecified" ($9.0M, 98.7% of total).
Odefsey is associated with 6 research studies, including "A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects" ($4.5M).